Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study on the Safety of Mogamulizumab for Patients with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a type of cancer called Cutaneous T-Cell Lymphoma (CTCL), specifically the subtypes known as Mycosis Fungoides and Sézary Syndrome. These are rare forms of cancer that affect the skin. The treatment being tested in this study is a medication called Mogamulizumab, which is also known by its code names KW-0761 and AMG 761. This medication is given as an infusion, which means it is administered directly into the bloodstream through a vein.

The purpose of the study is to evaluate the safety and tolerability of Mogamulizumab when given every four weeks to participants whose cancer has returned or has not responded to previous treatments. Participants will receive the medication over a period of up to 24 weeks. During the study, researchers will monitor participants for any side effects and changes in their health, including laboratory tests and physical examinations.

This study aims to gather important information about how the body responds to Mogamulizumab and to understand its effects on the cancer. The study will also look at how the medication is processed in the body and whether the immune system produces any antibodies against it. This information will help determine the potential benefits and risks of using Mogamulizumab for treating Cutaneous T-Cell Lymphoma.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the participant will have signed an informed consent form. This document confirms understanding of the study and agreement to participate.

    Eligibility is confirmed through a series of assessments, including age, medical history, and previous treatments for cutaneous T-cell lymphoma (CTCL).

  2. Step 2

    Initial assessment

    An initial assessment is conducted to confirm the diagnosis of mycosis fungoides or Sézary syndrome, which are subtypes of CTCL.

    The participant's overall health status is evaluated, including blood tests to check liver and kidney function, and a pregnancy test for women of childbearing potential.

  3. Step 3

    Treatment initiation

    The treatment involves the administration of mogamulizumab, a medication given as an intravenous injection.

    The initial phase includes more frequent dosing to establish the treatment's effectiveness and safety.

  4. Step 4

    Ongoing treatment

    After the initial phase, mogamulizumab is administered every four weeks.

    The participant will continue to receive this treatment as long as it is deemed beneficial and safe.

  5. Step 5

    Monitoring and follow-up

    Regular monitoring is conducted to assess the participant's response to the treatment. This includes physical examinations, blood tests, and other necessary evaluations.

    The study aims to observe any side effects and changes in health status, ensuring the participant's safety throughout the trial.

  6. Step 6

    Completion of the study

    The study is expected to conclude by September 30, 2025.

    Upon completion, a final assessment will be conducted to evaluate the overall impact of the treatment on the participant's condition.

Who can join the trial?

13 criteria

  • You must voluntarily sign and date an approved informed consent form before any study-related procedures begin.
  • You must be 18 years of age or older.
  • You must have a confirmed diagnosis of **mycosis fungoides (MF)** or **Sézary syndrome (SS)**, which are specific types of skin conditions.
  • You must have tried at least one previous treatment for your condition that did not work. This could include treatments like interferon, bexarotene, or chemotherapy. A treatment called **psoralen plus UVA** is not considered a systemic therapy.
  • You must have a performance status score of 0 or 1, which means you are fully active or have some symptoms but can still carry out light work.
  • Any side effects from previous cancer treatments must be mild or resolved.
  • Your blood health must be adequate, meaning you have enough white blood cells and platelets.
  • Your liver function must be adequate, with specific levels of liver enzymes and bilirubin.
  • Your kidney function must be adequate, with a creatinine clearance of at least 30 mL/min.
  • If you have been treated with certain antibodies before, you can still participate if your CD4+ cell counts are at least 200/mm3.
  • If you have a history of a specific type of bacterial infection, you can participate if you are on stable doses of preventive antibiotics.
  • If you are a woman who can become pregnant, you must have a negative pregnancy test before starting the study medication.
  • If you are a woman who can become pregnant, you must agree to use effective birth control methods during the study and for 6 months after the last dose. This includes methods like oral contraceptives or a double barrier method (such as a condom plus spermicide).

Who cannot join the trial?

6 criteria

  • Patients who have a different type of cancer that is not **mycosis fungoides** or **Sézary syndrome**. These are specific types of skin lymphoma.
  • Patients who are currently receiving other treatments for their cancer that might interfere with the study medication.
  • Patients who have a serious infection that is not well controlled. This means the infection is not being managed effectively with treatment.
  • Patients who have a history of severe allergic reactions to similar medications. An allergic reaction is when the body reacts negatively to a substance.
  • Patients who are pregnant or breastfeeding. This is to ensure the safety of the unborn baby or nursing child.
  • Patients who have any other medical condition that the study doctors believe would make it unsafe for them to participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Mogamulizumab is a medication being studied for its safety and tolerability in patients with certain types of skin lymphoma, specifically mycoses fungoides and Sézary syndrome. It is given to patients who have not responded to previous treatments or whose cancer has returned. The study involves administering this medication every four weeks to see how well patients tolerate it and to monitor any side effects.

What is already known about the treatment

Mogamulizumab – This medication is administered as an intravenous infusion, typically given every four weeks. It is currently being studied in clinical trials for its safety and effectiveness in treating relapsed or refractory cutaneous T-cell lymphoma, specifically the mycosis fungoides and Sézary syndrome subtypes. Mogamulizumab works by targeting a specific protein on the surface of certain immune cells, helping the body's immune system to attack and destroy cancer cells. It is classified as a monoclonal antibody, a type of targeted cancer therapy.

Investigated diseases

  • Mycosis Fungoides

    This is a type of cutaneous T-cell lymphoma, which is a cancer that starts in the white blood cells and affects the skin. It often begins with skin patches that may be red, scaly, and itchy. Over time, these patches can thicken into plaques or tumors. The disease can progress slowly, and in some cases, it may spread to other parts of the body, including the lymph nodes and internal organs. The progression can vary greatly among individuals, with some experiencing only mild skin symptoms for many years.

  • Sézary Syndrome

    This is a rare form of cutaneous T-cell lymphoma characterized by the presence of cancerous T-cells in the blood. It typically presents with widespread skin redness, itching, and scaling, along with enlarged lymph nodes. Unlike mycosis fungoides, Sézary syndrome involves both the skin and the blood from the onset. The disease can lead to significant discomfort due to skin symptoms and may progress to involve other organs. The course of the disease can be variable, with some patients experiencing more aggressive progression.

Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-515921-27-00Protocol code0761-016Estimated enrolment34 patientsSponsorKyowa Kirin Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).